Fig. 6.
The antitumor activity of Th9IL-4+IL-1β cells in vivo. C57BL/6 mice were challenged with 1 × 105 B16 cells delivered intravenously. T cells were differentiated as in Fig. 2, and 1 × 106 tyrosinase-related protein (TRP)-1 T cells were transferred on day 6 after tumor challenge. a, b TRP-1-specific classic Th9IL-4+TGF-β cells or Th9IL-4+IL-1β cells were transferred into tumor-bearing mice, tumor foci in the lung were counted on day 16 (a) or day 40 (b) after tumor inoculation (n = 5 mice/group). c The survival rate of tumor-bearing mice with the indicated treatments (n = 10 mice). d The survival rate of tumor-bearing mice with the indicated treatments (n = 10 mice). Control IgG or αIL-9 were injected intraperitoneally twice every week starting at 1 day before intravenous transfer of T cells. Data are mean ± SD; *P < 0.05, **P < 0.01, Student’s t test. Representative results from one of two repeated experiments are shown